RPCAR01 starts a phase 1 study, albeit one sponsored by academics.

Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.

Early data with ELVN-001 hold up well against olverembatinib and TERN-701.

Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.